Stockreport

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Prelude Therapeutics Incorporated  (PRLD) 
PDF WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology [Read more]